Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas....
Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Non-Small Cell Lung Cancer: Likelihood of Approval
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Non-Small Cell Lung Cancer....
Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Metastatic Colorectal Cancer: Likelihood of Approval
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Metastatic Colorectal Cancer. According...
Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Human Epidermal Growth Factor...
Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Adenocarcinoma Of The Gastroesophageal...
Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Gastric Cancer: Likelihood of Approval
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Gastric Cancer. According to...
Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Cervical Cancer: Likelihood of Approval
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Cervical Cancer. According to...
Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Breast Cancer: Likelihood of Approval
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Breast Cancer. According to...
Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Endometrial Cancer: Likelihood of Approval
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Endometrial Cancer. According to...
Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Transitional Cell Carcinoma (Urothelial...
Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Head And Neck Cancer: Likelihood of Approval
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Head And Neck Cancer....
Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Solid Tumor: Likelihood of Approval
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Solid Tumor. According to...
Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Human Epidermal Growth Factor...
Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Adenocarcinoma Of The Gastroesophageal...
Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Gastric Cancer: Likelihood of Approval
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Gastric Cancer. According to...